IndustryCompany release

electroCore Q3 sales rise 12% to $9.7M; 510(k) filed for Quell in CIPN

🇺🇸 electroCore, Inc. (ECOR) · Wed 04 Nov 2026

The bioelectronic medicine company narrowed its quarterly loss to $1.3 million and has asked the FDA to clear Quell for chronic chemotherapy-induced peripheral neuropathy.

electroCore reported net sales of $9.7 million for the third quarter of 2026, about 12% higher than a year earlier. The company announced the results on 4 November 2026 and posted a net loss of $1.3 million for the period.

The company attributed the growth to prescription sales of gammaCore and Quell Fibromyalgia to the U.S. Department of Veterans Affairs.

On the regulatory front, electroCore said it submitted a 510(k) premarket notification to the US Food and Drug Administration in October 2026. The filing follows a meeting with the agency and seeks clearance of Quell for chronic chemotherapy-induced peripheral neuropathy (CIPN).

For context, a 510(k) is the premarket route by which a device maker shows that its product is substantially equivalent to a legally marketed predicate device. The FDA has not yet made a decision on the submission, and no clearance timeline was provided in the information available.

What it means for your team

  • Regulatory teams can note that electroCore has filed a 510(k) for a CIPN indication, so any FDA clearance would extend Quell beyond its fibromyalgia use.
  • Market-access teams should note that the Department of Veterans Affairs is the main driver of current sales growth for gammaCore and Quell Fibromyalgia.
  • The 510(k) is pending, and no decision date has been disclosed.

Company's press release (SEC filing): electroCore, Inc. ↗

Article written by VigiEye from the official source (electroCore, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →